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Introduction: A freely available, culturally valid
depression screening tool is required for use by
primary care services across Australia to screen for
depression in Aboriginal and/or Torres Strait Islander
populations. This is the protocol for a study aiming to
determine the validity, sensitivity and specificity of the
culturally adapted 9-item Patient Health Questionnaire
(aPHQ-9).
Methods and analysis: Cross-sectional validation
study. A total of 500 people who self-identify as
Aboriginal and/or Torres Strait Islander, are ≥18 years
of age, attending 1 of 10 primary healthcare services
or service events across Australia and able to
communicate sufficiently to answer study questions
will be recruited. All participants will complete the
aPHQ-9 and the criterion standard MINI International
Neuropsychiatric Interview (MINI) 6.0.0. The primary
outcome is the criterion validity of the aPHQ-9.
Process outcomes related to acceptability and
feasibility of the aPHQ-9 will be analysed only if the
measure is found to be valid.
Ethics and dissemination: Lead ethical approval
was obtained jointly from the University of Sydney
Human Research Ethics Committee (project 2014/361)
and the Aboriginal Health and Medical Research
Council of New South Wales (project 1044/14).
Results will be disseminated via the usual scientific
forums, including peer-reviewed publications and
presentations at international conferences following
presentation to, discussion with and approval by
participating primary healthcare service staff and
community.
Trial registration number: ACTRN12614000705684.
BACKGROUND
There is a need to focus our attention on
overcoming the health disadvantage experi-
enced by the world’s more than 370 million
Indigenous peoples.1 In Australia, chronic
disease (cardiovascular disease, cerebrovascu-
lar disease, diabetes, chronic kidney disease
and chronic obstructive pulmonary disease)
accounts for 80% of the life expectancy gap
experienced by Aboriginal and/or Torres
Strait Islander (hereafter referred to as
Indigenous) people2 who are estimated to
make up 3% (669 900 people) of the total
Australian population.3
It is estimated that up to 20% of the
general population with chronic disease will
have a diagnosis of comorbid major depres-
sion.4 Approximately similar proportions will
additionally meet criteria for moderate or
minor depression.5 6 Among people with
existing chronic disease, comorbid depres-
sion is associated with increased disability,
longer length of hospital stay, reduced
quality of life and higher costs among those
who experience an acute vascular event.4 7
Major depression also signiﬁcantly
Strengths and limitations of this study
▪ The main strengths of the current study are that
it will determine the criterion validity of a cultur-
ally adapted depression screening tool (aPHQ-9)
for use across multiple States and Territories
across Australia.
▪ A widely used psychiatric structured diagnostic
interview, the MINI International Neuropsychiatry
Interview (MINI) 6.0.0, is the reference standard.
▪ There are insufficient resources, nor will it be
feasible, to use the ultimate reference standard
reference measure, an experienced culturally
competent psychiatrist or highly trained mental
health clinician using a semistructured clinical
interview.
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complicates the long-term management of comorbid
conditions by negatively impacting on adherence to
medications and other secondary preventive strategies.8
Mental illness and depression are also considered to
be key contributors to the development of chronic
disease.9–12 The presence of depression approximately
doubles the risk of ﬁrst myocardial infarction or cardiac
death, but among patients with established ischaemic heart
disease, the risk of a future serious cardiovascular event is
increased three to fourfold by comorbid depression.6 13
However, none of this research has been conducted with,
by or in Indigenous populations in Australia.
The identiﬁcation and proactive management of
depression in general primary care in Australia has been
shown to improve outcomes (reduced depression and
improved treatment intensiﬁcation sustained over
12 months, with a reduction in 10-year cardiovascular
disease risk) in people with diabetes and heart disease.14
A freely available, culturally valid depression screening
tool for use across Australia is required to achieve the
same beneﬁt in Indigenous peoples attending primary
care.
Two screening tools for depression have been deter-
mined valid, in comparison with semistructured clinical
interviews, for use by Indigenous Australians residing in
speciﬁc Australian communities. The more comprehen-
sive validation study is of the Kimberley Indigenous
Cognitive Assessment of Depression (KICA-dep) scale.
This study was conducted with 250 Indigenous people
(18 with depressive disorder) aged 45 years or more res-
iding in 6 communities in the Kimberley region.15 In
the other study, the 9-item Patient Health Questionnaire
(PHQ-916) was adapted for use in a small sample (n=34,
9 with depression) of Aboriginal primary care patients
with coronary heart disease attending a single primary
healthcare centre in the Northern Territory in
Australia.17 In a subsequent conceptual adaptation
study,18 19 the original PHQ-9 was assessed by men from
ﬁve Aboriginal language groups in Central Australia as
requiring modiﬁcation for use in their community and
was modiﬁed (adapted 9-item Patient Health
Questionnaire, aPHQ-9) accordingly to ensure cross-
cultural validity, and found valid in a community sample
of 78 Indigenous people from Central Australia. No
measure has been validated in more than one Australian
State or Territory.
Aims
The primary aim is to determine the validity of the
aPHQ-9,18 compared against a reference standard (cri-
terion standard) MINI International Neuropsychiatric
Interview (MINI) 6.0.020 as a screening instrument for
depression. The secondary aim is to determine the con-
tribution that seven additional questions identiﬁed
during indepth qualitative research make to the detec-
tion of depression via the aPHQ-9 in Indigenous people
attending primary healthcare services. A process evalu-
ation will be conducted following the completion of
recruitment to formally evaluate the processes, lessons
learnt and impact of implementing the study on recruit-
ment sites and staff. Process evaluation methods will be
described in a separate protocol.
METHODS
‘Getting it Right’ is a national, multicentre, prospective
diagnostic accuracy, observational study to be conducted
through a network of Indigenous primary healthcare
services across Australia’s States and Territories. The
study was conceived, designed and will be conducted in
keeping with the principles of Reciprocity, Respect,
Equality, Responsibility, Survival and Protection and
Spirit and Integrity important to Aboriginal and Torres
Strait Islander communities and described in the
National Health and Medical Research Council’s Values
and ethics: guidelines for ethical conduct in Aboriginal and
Torres Strait Islander health research.21 The investigator
team includes Aboriginal and non-Aboriginal research-
ers, relationships will be developed between the project
team and key personnel at each service, local commu-
nity members will be employed at each service to under-
take data collection, the data collected at each site will
remain the property of that site, feedback sessions will
be conducted at each service for staff and community
members and services and individual research partici-
pants will receive compensation for participation.
PARTICIPANTS
The study will be conducted in ∼10 urban, rural and
remote primary healthcare services (sites) in Australia
with a predominantly Indigenous client base.
Consent process and participant inclusion and exclusion
criteria
Written approval from each participating site’s Board, if
a community-controlled organisation, institutional
review board, research committee, community jury,
letter of support or similar must be obtained, as well as
from any local Human Research Ethics Committee or
other relevant regional or national body, before recruit-
ment can start.
Inclusion criteria
All patients are eligible for the study if, at the time of
presentation at a participating health service or commu-
nity event, they meet each of the following criteria:
1. ≥18 years of age,
2. self-identiﬁes as Aboriginal and/or Torres Strait
Islander,
3. able to communicate sufﬁciently to answer study
questions,
4. able to give informed consent.
Exclusion criteria
Patients will be excluded from the study if at the time of
presentation, they are known (diagnosis documented in
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medical records or information provided when asked)
to have psychosis or bipolar disorder.
Recruitment
Consecutive eligible patients will be invited to participate
in the study on any given recruitment day. Trained staff
members nominated by each service will obtain individ-
ual participant written or verbal consent to participate
in the study. Recruitment began on 25 March 2015 and
will continue until 500 participants have completed both
interviews.
Background care
All patients within the primary healthcare service or
people attending service-led events will be managed by
their general practitioner or other allied health profes-
sional. Their management should be best practice stand-
ard of care according to regional guidelines and the
duty of care always remains with the healthcare service.
Study outcome
The primary outcome is the criterion validity of the
aPHQ-9.18 The reference standard is a clinical diagnosis
of depression ascertained using the MINI 6.0.0,20 having
two categories: ‘current major depressive episode’ and
‘no current major depressive episode’.
In addition, we also aim to determine the contribution
that seven additional questions identiﬁed during
indepth qualitative research make to the detection of
depression via the aPHQ-9,18 criterion validity of the
aPHQ-2 (the ﬁrst two questions of the aPHQ-9) and
feasibility of assessment using the aPHQ-9 within
primary healthcare services. Should the aPHQ-9 (with
or without the addition of one or more of the seven
additional questions) have acceptable sensitivity and spe-
ciﬁcity as a screening tool for depression, we will seek
qualitative feedback on feasibility from primary health-
care staff during the ‘feedback of study results’ to sites.
Site staff will be asked about the impact of screening on
them, their study participants and the practice, the
effect on the participant/health-professional relation-
ship, the usefulness of the aPHQ-9 and the extent to
which practice routines must be adapted to integrate the
aPHQ-9 into their service delivery should it be found to
be valid.
Data collection
During recruitment, consecutive patients attending the
primary healthcare service on a recruitment day or
people attending service events, who appear to meet the
inclusion criteria, will be approached by a trained clinic
staff member. Site study staff will record the date of pres-
entation of all people considered for participation in
the study on the study screening log, whether they were
eligible, whether they consented to participate and if
not, the reason for non-participation. All consecutive
consenting participants will be recorded on the study
enrolment log.
TEST METHODS
The aPHQ-9 and its development have been described
previously.18 In brief, the PHQ-9 was modiﬁed to ensure
cross-cultural validity. A structured process was followed
using the expertise of ﬁve focus groups comprising male
members of distinct Indigenous language groups in
central Australia. Bilingual experts from each language
group translated the PHQ-9. Each translation was dis-
cussed with the research team, clarity sought on
meaning for difﬁcult items and problematic translations
were identiﬁed, discussed and amended (where neces-
sary). This resulted in some words and phrases being
modiﬁed to provide linguistic or conceptual equiva-
lence, and single questions with divergent English mean-
ings being split into two. During the modiﬁcation
process, seven key features of depression in Aboriginal
men were identiﬁed that were not covered by the
aPHQ-9. These additional features include anger, wea-
kened spirit, homesickness, irritability, excessive worry,
rumination and drug/alcohol use.
Reference standard: MINI 6.0.0
The MINI22 is a short, structured interview for the major
Axis I psychiatric disorders. Validation and reliability
studies have shown that the MINI has acceptably high
validation and reliability scores compared with the
Structured Clinical Interview for DSM Disorders and the
World Mental Health Composite International
Diagnostic Interview, can be administered within 19 min
on average and can be modularised and administered by
clinicians and lay interviewers after appropriate training.
The MINI is the most widely used psychiatric structured
diagnostic interview instrument in the world and has
been validated for use in over 100 countries. There are
insufﬁcient resources (trained personnel) available, nor
will it be feasible, to use the ultimate reference standard
method of diagnosis of depression by an experienced
culturally competent psychiatrist or highly trained
mental health clinician using a semistructured clinical
interview.
Assessment 1
Following consent, a trained member of the primary
healthcare service staff will interview each participant
using a short paper-based or computer-assisted question-
naire during a face-to-face interview (or telephone if
required). Participants can answer questions directly
using paper-based or computer-assisted forms or the
questionnaire can be interviewer-administered at the dis-
cretion of the interviewer and participant. Data will be
collected on the method of assessment (interviewer-
administered or self-completed, paper-based or
computer-assisted, language in which interviews were
conducted), response to the 11 questions on the
aPHQ-9, the additional seven questions, one question
regarding how much any identiﬁed problems impact on
their daily lives, and questions about the acceptability
and ease of use of the aPHQ-9. These questions are
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followed by an open-ended question where participants
can provide feedback about the aPHQ-9. Study staff will
encourage participants to provide feedback about
aPHQ-9 acceptability and any issues of concern.
Demographic information to be collected includes
gender, age, whether Aboriginal language(s) is spoken
at home, marital status, living arrangements (alone/with
others), recent activity-restricting illness, recent (in the
last 2 months) bereavement, highest educational qualiﬁ-
cation, lifetime and current occupation, main income
earner and medical history (primary history of chronic
disease and mental illnesses and whether any associated
medications are taken).
If a participant has difﬁculty reading or requires any
assistance for whatever reason, the aPHQ-9 will be read
to them by a trained member of staff or an interpreter.
This person will also enter the responses on to the
paper or computer-assisted form on behalf of the partici-
pant. All data will be entered in the secure web-based
study database.
Assessment 2
On the same day, or within 7 days of completing assess-
ment 1, all participants will be administered the MINI
6.0.0 interview and questions on smoking and alcohol
consumption in a face-to-face (or telephone if required)
interview by a trained MINI interviewer who did not
complete and will be blind to the results of assessment 1.
Three MINI 6.0.0 modules will be administered for this
study: the full set of major depressive episode/disorder
questions (current, recurrent), post-traumatic stress dis-
order (past month) and generalised anxiety disorder
(past 6 months). These will be followed by questions
about smoking and alcohol consumption.
Coenrolment
There are no methodological contraindications to coen-
rolment of participants into other research projects.
Training
Prior to initiation of the study at any site, all participat-
ing primary healthcare service staff involved in the study
will receive study-speciﬁc training. Training relates to the
study protocol, source documentation, screening and
enrolment logs, Good Clinical Research Practice,
informed consent, questionnaire completion, interview-
ing participants for research purposes, safety protocols,
accessing and completing data entry on the study-
speciﬁc secure internet-based study database, and study
documentation. Training will be provided in person by
SF (the project manager) and MLH (the chief investiga-
tor) in the ﬁrst instance. Subsequent retraining, or train-
ing of new staff may be provided via telephone and/or
video links where available.
Training related to administration and scoring of the
MINI will be provided face to face or via video link by
NG (the study psychiatrist). This will be followed by
inter-rater assessments of up to four prerecorded role
plays. Prerecorded role plays will be scored by NG, who
will inform SF when the MINI interviewers are compe-
tent. Sites will only be activated after MINI results have
been checked by and discussed with NG.
Safety
The safety and welfare of the participants is of primary
importance in the study. Participation is voluntary and
non-participation will in no way affect the quality of care
provided to the participant by study staff. We will work
with each primary healthcare service to ensure depres-
sion, deliberate self-harm and suicidal ideation and
intent protocols are in place for follow-up and care of
study participants.
We require one nominated responsible person at each
recruiting primary healthcare service to check all com-
pleted aPHQ-9 questionnaires at the end of each day. In
addition, we will notify the primary healthcare service of
any participant who:
1. scores 10 or more on the aPHQ-9 assessment, and/or
2. is considered to have a major depressive episode
during the MINI interview,
3. indicates suicidal ideation or suicidal intent during
the aPHQ-9 or the MINI interview.
The primary healthcare service will be notiﬁed by way
of a standard email. The email will indicate our reason
for concern and provide some suggestions on clinical
management options based on current guidelines.
Completed case report forms can be printed by inter-
viewers and (or electronically) attached to medical
records to facilitate ongoing clinical assessment.
We will provide local (to each site) mental health
crisis line numbers and access to online psychological
interventions (http://www.ecouch.com.au, http://www.
mindspot.org.au). Study staff may also offer to email this
information to participants.
The suggestions in our email to the primary health-
care service are:
1. Consider non-pharmacological treatments such as
advising an increase in social outlets, regular exercise
or referral to a clinical psychologist. Clinical psych-
ology can be accessed through the Medicare Better
Access initiative and is available free of charge to
Australian residents and citizens. There is provi-
sion for up to 10 sessions per year as part of a GP
mental health treatment plan http://www.health.gov.
au/internet/main/publishing.nsf/content/mental-ba-
gpsamp
2. If you feel that antidepressant medication is neces-
sary, then either yourself or their treating doctor
might consider the attached guidelines, https://www.
nice.org.uk/guidance/cg90.23
3. Consider referral to a specialist, for example, psych-
ologist or psychiatrist.
Participants can opt to have any detected condition
NOT communicated to their clinician unless it is felt
that the level of risk is so great that we need to breach
conﬁdentiality: a HIGH on the suicidality risk level on
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the MINI. Site study staff will be able to contact the




We computed the sample size based on the target preci-
sion for the estimation of sensitivity and speciﬁcity of the
aPHQ-9 used for the screening of a major depressive
episode. Assuming a major depressive episode preva-
lence (assessed by the MINI) of 10% and a true sensiti-
vity of 0.85, a sample size of 500 participants will give us
a precision of 0.1 for the sensitivity’s 95% CI. For the
speciﬁcity, 500 participants will provide a precision of
0.04 for the speciﬁcity’s 95% CI, assuming a true speciﬁ-
city of 0.75 and the same prevalence of 10%. If the
prevalence of major depressive episodes is in fact higher,
for example, 15%, the precision for the sensitivity will
be 0.08. For the analysis of the contribution of add-
itional questions to the aPHQ-9, a sample size of 500 will
give us 80% probability (power) of detecting a true
improvement of 0.05 in the area under the ROC curve,
ﬁxing the type I error at 0.05.
Data analysis
For descriptive purposes, baseline characteristics will be
presented. Discrete variables will be summarised by fre-
quencies and percentages, continuous variables by use
of standard measures of central tendency and disper-
sion, mean and SD or median and IQR.
Primary aim analyses
We will assess the validity of the aPHQ-9 when compared
with the MINI, using two common criteria for major
depression: I—a score of 2 or above on one of the ﬁrst
two items of the aPHQ-9 plus 4 or more items with a
score of 2 or above (the last question is counted if a
score of 1 or above is indicated) and II—a total score of
10 points or above, similar to the usual cut-off for the
original PHQ-9.24 The original scoring method will be
used with the two ‘split questions’ (questions 5 and 8 on
the original PHQ-9) on the aPHQ-9 being scored once
only. However, given this is an adaptation of the original
questionnaire, we will explore the properties of other
cut-off points by constructing an ROC curve. The sensi-
tivity and speciﬁcity will also be computed for subgroups
(eg, individuals with chronic disease) using logistic
regressions to allow adjustment for potential demo-
graphic differences between the subgroups. All the esti-
mates will be presented with 95% CIs.
Secondary aim analyses
We will assess the validity of the aPHQ-9 plus the add-
itional seven culturally speciﬁc questions when com-
pared with the MINI. The contribution of each question
will be initially analysed separately and we will select for
further analysis any questions that individually
contribute to a better discrimination property of the
questionnaire while maintaining the internal validity of
the instrument. We will compare the area under the
ROC curves of the original score with the one obtained
by individually adding each question, in the total
sample, and in those with, and in those without chronic
disease. We will also compute Cronbach’s α to evaluate if
the new question is measuring the same underlying con-
struct as the aPHQ-9.
After this step, we will use a stepwise strategy to evalu-
ate the addition of multiple questions to the aPHQ-9.
We will ﬁrst consider the aPHQ-9 plus the question with
highest improvement in the area under the ROC curve,
then we will add the second best question and evaluate
if this question still contributes to an increase in the
area under the ROC curve and so on. If any of the addi-
tional questions prove to be useful, we will study the psy-
chometric properties of this new instrument in more
detail, as well as recommend major depressive episode
screening cut-points.
Missing outcome data
The calculation of the global score for the aPHQ-9 is
given by the sum of all the answers on the questionnaire.
If one question is left unanswered, the score cannot be
directly computed. For incomplete questionnaires, as
long as there are ﬁve or more questions answered, we
will compute a partial score summing the answered
questions. Then, the global score will be derived with a
proportional transformation of the partial scores, based
on the number of unanswered questions. For example,
if a participant has a partial score of 12 based on 8 ques-
tions, the global score will be computed as
(12×9)÷8=13.5. The underlying assumption for this pro-
cedure is that the unanswered question(s) follows a
similar pattern to the answered ones. If a questionnaire
has only four or fewer questions answered, it will be
excluded from the analysis. For other variables in the
study, we will use all the available information for the
respective analysis.
Data management
The internet-based data management system will be
managed centrally by the project manager from The
George Institute for Global Health. Registration and
data entry will be performed at the participating sites via
a password-protected connection. Only trained staff
listed in the delegation log will be given unique pass-
words to access the database. Paper case report forms
will be provided to sites preferring to use these for
initial data collection.
Confidentiality and privacy
Every precaution will be taken to respect the privacy of
study participants. Each participant’s MINI result will be
provided to and checked by the primary healthcare
service. The general practitioner of a participant who is
assessed as experiencing a psychiatric disorder will be
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encouraged to arrange reassessment, treatment or
formal referral for depressive or other abnormal mood
symptoms according to their clinical judgement.
DISSEMINATION
The ﬁndings of this study will be disseminated via the
usual scientiﬁc forums, including peer-reviewed publica-
tions and presentations at international conferences fol-
lowing presentation to, discussion with and approval by
participating primary healthcare service staff and com-
munity. Participants will have the option to receive infor-
mation (via post, text or email) on the study ﬁndings,
when available. The study will be administered by the
George Institute for Global Health, with the design and
conduct overseen by a steering committee (authors).
This committee has expertise in Indigenous health, car-
diovascular health and mental health research. This
study will adhere to the National Health and Medical
Research Council Values and Ethics—Guidelines for
Ethical Conduct in Aboriginal and Torres Strait Islander
Health Research.
CONCLUSIONS
This study responds to the lack of understanding of the
natural history, trajectories and outcomes of depression
and comorbid chronic disease in the Indigenous people
of Australia, and the performance of primary healthcare
services in identifying and managing depression and
comorbid chronic disease. This work will directly con-
tribute to the evidence base for identifying depression
and developing culturally speciﬁc primary healthcare
depression interventions for Indigenous people by pro-
viding the evidence on whether to recommend the use
of the aPHQ-9 as a screening tool for depression. If vali-
dated, the aPHQ-9 will enable exploration of the burden
and correlates of depressive symptoms with comorbid
chronic disease and chronic disease risk factors in
Indigenous patients routinely attending primary health-
care and assessment of the effectiveness of management
strategies for depression in Indigenous patients routinely
attending primary healthcare.21
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